Active Biotech (ACTI) Company presentation summary

Strategic focus and pipeline

• Refocused on specialist disease areas with large unmet medical needs, particularly in oncology and inflammation.

• Key assets include tasquinimod for hematological malignancies and laquinimod for inflammatory eye disorders.

• Tasquinimod is in Phase I/II trials for myelofibrosis, with Orphan Drug Designation granted by the FDA.

• Laquinimod development continues with a partner, targeting non-infectious uveitis and other eye disorders.

• Naptumomab is licensed to NeoTX for global development in solid tumors, with ongoing clinical studies.

Clinical development highlights

• Tasquinimod shows disease-modifying potential in myelofibrosis, with ongoing clinical proof-of-concept studies in the US and Europe.

• Preclinical data indicate synergy with JAK and BET inhibitors, and efficacy as both monotherapy and in combination.

• Two clinical trials for tasquinimod in myelofibrosis are ongoing, with interim results expected in 2026 and final results in 2027.

• Laquinimod eye drops demonstrated safety, tolerability, and effective ocular distribution in Phase I trials.

• The LION study confirmed laquinimod's ability to reach therapeutic concentrations in both anterior and posterior eye segments.

Market opportunity and unmet needs

• Myelofibrosis and non-infectious uveitis represent significant unmet medical needs with high market potential.

• Myelofibrosis market projected to reach $2.9 billion in top eight global markets by 2031.

• Non-infectious uveitis has a $1.5 billion market opportunity by 2033, with no approved eye drop formulations currently available.

• Tasquinimod and laquinimod benefit from strong patent protection extending into the 2040s.

• Orphan Drug Designation provides regulatory advantages, including market exclusivity and fee waivers.